- Home
- GLMD vs PCSA Comparison
GLMD vs PCSA Comparison
Compare GLMD & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- PCSA
- Stock Information
- Founded
- GLMD 2000
- PCSA 2011
- Country
- GLMD Israel
- PCSA United States
- Employees
- GLMD N/A
- PCSA N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- PCSA Health Care
- Exchange
- GLMD Nasdaq
- PCSA Nasdaq
- Market Cap
- GLMD 3.0M
- PCSA 3.3M
- IPO Year
- GLMD 2014
- PCSA N/A
- Fundamental
- Price
- GLMD $1.94
- PCSA $0.23
- Analyst Decision
- GLMD Hold
- PCSA Strong Buy
- Analyst Count
- GLMD 1
- PCSA 1
- Target Price
- GLMD N/A
- PCSA $2.00
- AVG Volume (30 Days)
- GLMD 413.3K
- PCSA 48.0M
- Earning Date
- GLMD 08-27-2025
- PCSA 08-12-2025
- Dividend Yield
- GLMD N/A
- PCSA N/A
- EPS Growth
- GLMD N/A
- PCSA N/A
- EPS
- GLMD N/A
- PCSA N/A
- Revenue
- GLMD N/A
- PCSA N/A
- Revenue This Year
- GLMD N/A
- PCSA N/A
- Revenue Next Year
- GLMD N/A
- PCSA N/A
- P/E Ratio
- GLMD N/A
- PCSA N/A
- Revenue Growth
- GLMD N/A
- PCSA N/A
- 52 Week Low
- GLMD $1.15
- PCSA $0.15
- 52 Week High
- GLMD $23.80
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- GLMD 63.61
- PCSA 46.56
- Support Level
- GLMD $1.74
- PCSA $0.22
- Resistance Level
- GLMD $2.22
- PCSA $0.28
- Average True Range (ATR)
- GLMD 0.13
- PCSA 0.03
- MACD
- GLMD 0.02
- PCSA 0.00
- Stochastic Oscillator
- GLMD 67.80
- PCSA 34.02
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).